Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Total Valuation
Tenaya Therapeutics has a market cap or net worth of $163.27M. The enterprise value is $219.84M.
Market Cap$163.27M
Enterprise Value$219.84M
Share Statistics
Tenaya Therapeutics has 216,505,890 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding216,505,890
Owned by Insiders71.20%
Owned by Institutions8.39%
Financial Efficiency
Tenaya Therapeutics’s return on equity (ROE) is -1.20 and return on invested capital (ROIC) is -108.62%.
Return on Equity (ROE)-1.20
Return on Assets (ROA)-0.93
Return on Invested Capital (ROIC)-108.62%
Return on Capital Employed (ROCE)-1.12
Revenue Per Employee0.00
Profits Per Employee-1.15M
Employee Count97
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Tenaya Therapeutics is ―. Tenaya Therapeutics’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio1.31
Price to Fair Value1.31
Price to FCF-1.33
Price to Operating Cash Flow-2.83
PEG Ratio0.05
Income Statement
In the last 12 months, Tenaya Therapeutics had revenue of 0.00 and earned -111.13M in profits. Earnings per share was -1.31.
Revenue0.00
Gross Profit-8.47M
Operating Income-115.95M
Pretax Income-111.13M
Net Income-111.13M
EBITDA-102.66M
Earnings Per Share (EPS)-1.31
Cash Flow
In the last 12 months, operating cash flow was -72.71M and capital expenditures -755.00K, giving a free cash flow of -73.47M billion.
Operating Cash Flow-72.71M
Free Cash Flow-73.47M
Free Cash Flow per Share-0.34
Dividends & Yields
Tenaya Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.82
52-Week Price Change-50.34%
50-Day Moving Average1.29
200-Day Moving Average0.95
Relative Strength Index (RSI)33.00
Average Volume (3m)4.00M
Important Dates
Tenaya Therapeutics upcoming earnings date is Mar 24, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Tenaya Therapeutics as a current ratio of 4.22, with Debt / Equity ratio of 13.91%
Current Ratio4.22
Quick Ratio4.22
Debt to Market Cap0.02
Net Debt to EBITDA-0.09
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Tenaya Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Tenaya Therapeutics EV to EBITDA ratio is -1.27, with an EV/FCF ratio of -1.43.
EV to Sales0.00
EV to EBITDA-1.27
EV to Free Cash Flow-1.43
EV to Operating Cash Flow-1.44
Balance Sheet
Tenaya Therapeutics has $56.31M in cash and marketable securities with $11.53M in debt, giving a net cash position of $44.78M billion.
Cash & Marketable Securities$56.31M
Total Debt$11.53M
Net Cash$44.78M
Net Cash Per Share$0.21
Tangible Book Value Per Share$1.09
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Tenaya Therapeutics is $9.57, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$9.57
Price Target Upside619.66% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast46.68%